US7301021B2
(en)
|
1997-07-02 |
2007-11-27 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
EP1473292A1
(de)
*
|
1997-11-03 |
2004-11-03 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatische heterocyclische Verbindungen als antiinflammatorische Mittel
|
WO1999023091A1
(en)
*
|
1997-11-03 |
1999-05-14 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as anti-inflammatory agents
|
WO1999032111A1
(en)
*
|
1997-12-22 |
1999-07-01 |
Bayer Corporation |
INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
|
KR100622138B1
(ko)
*
|
1997-12-22 |
2006-09-13 |
바이엘 코포레이션 |
아릴 및 헤테로아릴 치환 헤테로고리형 우레아를 사용한라프 키나제의 저해
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
JP2002534468A
(ja)
|
1999-01-13 |
2002-10-15 |
バイエル コーポレイション |
p38キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
|
EP1140840B1
(de)
*
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
|
CA2549558C
(en)
*
|
1999-01-13 |
2010-08-31 |
Bayer Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
UA73492C2
(en)
*
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
EP1157026A1
(de)
|
1999-02-22 |
2001-11-28 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Polyheterocyclische verbindungen mit entzündungshemmender wirkung
|
DE60023853T2
(de)
|
1999-03-12 |
2006-05-24 |
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield |
Aromatische heterozyklische verbindungen als antientzündungwirkstoffe
|
DE60014603T2
(de)
|
1999-03-12 |
2006-02-16 |
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield |
Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
|
DE60024830T2
(de)
|
1999-07-09 |
2006-06-14 |
Boehringer Ingelheim Pharma |
Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
|
WO2001036403A1
(en)
*
|
1999-11-16 |
2001-05-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Urea derivatives as anti-inflammatory agents
|
AU1781601A
(en)
|
1999-11-23 |
2001-06-04 |
Smithkline Beecham Corporation |
3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
|
US6525046B1
(en)
|
2000-01-18 |
2003-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as antiinflammatory agents
|
US6608052B2
(en)
|
2000-02-16 |
2003-08-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as anti-inflammatory agents
|
MXPA02009319A
(es)
*
|
2000-03-22 |
2003-03-12 |
Vertex Pharma |
Inhibidores de p38.
|
US6645990B2
(en)
|
2000-08-15 |
2003-11-11 |
Amgen Inc. |
Thiazolyl urea compounds and methods of uses
|
EP1415987B1
(de)
|
2000-10-20 |
2007-02-28 |
Eisai R&D Management Co., Ltd. |
Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
|
WO2002044156A2
(en)
|
2000-11-29 |
2002-06-06 |
Glaxo Group Limited |
Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
|
US6949567B2
(en)
|
2001-02-26 |
2005-09-27 |
4Sc Ag |
Compounds for the treatment of protozoal diseases
|
DE10109204A1
(de)
*
|
2001-02-26 |
2002-09-19 |
4Sc Ag |
Verbindungen zur Behandlung von Protozoen-Erkrankungen
|
EP1392661A1
(de)
|
2001-05-16 |
2004-03-03 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Diarylharnstoffderivate, die sich als entzündungshemmende mittel eignen
|
JP2004531571A
(ja)
|
2001-05-25 |
2004-10-14 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物
|
CA2446193C
(en)
|
2001-06-05 |
2011-11-01 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
1,4-disubstituted benzo-fused cycloalkyl urea compounds
|
DE60219793T2
(de)
|
2001-07-11 |
2008-01-24 |
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield |
Verfahren zur Behandlung von Cytokin-Vermittelten Erkrankungen
|
EP1438048A1
(de)
|
2001-10-18 |
2004-07-21 |
Boehringer Ingelheim Pharmaceuticals Inc. |
1,4-disubstituierte benzokondensierte harnstoffverbindungen als cytokinhemmer
|
DE10203086A1
(de)
*
|
2002-01-28 |
2003-07-31 |
Bayer Ag |
5-Ring Heterozyklen
|
EP2324825A1
(de)
|
2002-02-11 |
2011-05-25 |
Bayer Healthcare LLC |
Arylharnstoffe mit Angiogenese hemmender Aktivität
|
PT1580188E
(pt)
|
2002-02-11 |
2012-01-25 |
Bayer Healthcare Llc |
Aril-ureias como inibidores de cinases
|
US20040023961A1
(en)
*
|
2002-02-11 |
2004-02-05 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenisis inhibiting activity
|
ATE386030T1
(de)
|
2002-02-25 |
2008-03-15 |
Boehringer Ingelheim Pharma |
1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
|
WO2004004725A2
(en)
|
2002-07-09 |
2004-01-15 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
|
JP2006504667A
(ja)
|
2002-08-08 |
2006-02-09 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
炎症過程に関与するサイトカインの抑制剤としてのフッ素化フェニル−ナフタレニル−尿素化合物
|
US7268139B2
(en)
|
2002-08-29 |
2007-09-11 |
Scios, Inc. |
Methods of promoting osteogenesis
|
US7144911B2
(en)
|
2002-12-31 |
2006-12-05 |
Deciphera Pharmaceuticals Llc |
Anti-inflammatory medicaments
|
US7202257B2
(en)
|
2003-12-24 |
2007-04-10 |
Deciphera Pharmaceuticals, Llc |
Anti-inflammatory medicaments
|
MXPA05009104A
(es)
|
2003-02-28 |
2006-05-31 |
Bayer Pharmaceuticals Corp |
Derivados de urea biciclica novedosa utiles en el tratamiento del cancer y otros trastornos.
|
MXPA05010496A
(es)
*
|
2003-03-28 |
2005-11-16 |
Pharmacia & Upjohn Co Llc |
Moduladores alostericos positivos del receptor de acetilcolina nicotinico.
|
GB0320244D0
(en)
|
2003-05-06 |
2003-10-01 |
Aventis Pharma Inc |
Pyrazoles as inhibitors of tumour necrosis factor
|
ATE366108T1
(de)
|
2003-05-20 |
2007-07-15 |
Bayer Pharmaceuticals Corp |
Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
|
NZ580384A
(en)
|
2003-07-23 |
2011-03-31 |
Bayer Pharmaceuticals Corp |
4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
|
AU2004270733B2
(en)
|
2003-09-11 |
2011-05-19 |
Itherx Pharma, Inc. |
Cytokine inhibitors
|
US7244441B2
(en)
|
2003-09-25 |
2007-07-17 |
Scios, Inc. |
Stents and intra-luminal prostheses containing map kinase inhibitors
|
CN101337930B
(zh)
|
2003-11-11 |
2010-09-08 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
TW200530236A
(en)
|
2004-02-23 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Heteroaryl phenylurea
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
JP2007535565A
(ja)
|
2004-04-30 |
2007-12-06 |
バイエル ファーマシューティカルス コーポレーション |
癌の治療に有用な置換ピラゾリル尿素誘導体
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
EP1797881B1
(de)
|
2004-09-17 |
2009-04-15 |
Eisai R&D Management Co., Ltd. |
Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
|
JP2008523072A
(ja)
|
2004-12-07 |
2008-07-03 |
ルーカス ファーマシューティカルズ, インコーポレイテッド |
タンパク質キナーゼの阻害剤
|
JP2008523071A
(ja)
|
2004-12-07 |
2008-07-03 |
ルーカス ファーマシューティカルズ, インコーポレイテッド |
Mapキナーゼの尿素インヒビター
|
EP1831228A1
(de)
*
|
2004-12-20 |
2007-09-12 |
AstraZeneca AB |
Neue pyrazolderivate und deren verwendung als modulatoren nikotinischer acetylcholinrezeptoren
|
EP1835934A4
(de)
*
|
2004-12-23 |
2010-07-28 |
Deciphera Pharmaceuticals Llc |
Enzymmodulatoren und behandlungen
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
EP1676574A3
(de)
|
2004-12-30 |
2006-07-26 |
Johnson & Johnson Vision Care, Inc. |
Verfahren zur Förderung des Überlebens von Zell- und Gewebe-Transplantaten
|
GB0500435D0
(en)
*
|
2005-01-10 |
2005-02-16 |
Novartis Ag |
Organic compounds
|
DE602006017188D1
(de)
|
2005-03-07 |
2010-11-11 |
Bayer Schering Pharma Ag |
Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
|
DE102005015253A1
(de)
*
|
2005-04-04 |
2006-10-05 |
Merck Patent Gmbh |
Pyrazolderivate
|
EP2281901B1
(de)
|
2005-08-02 |
2013-11-27 |
Eisai R&D Management Co., Ltd. |
Pharmazeutische anti-tumor Zusammensetzung mit Angiogeneseinhibitoren
|
DE102005037499A1
(de)
*
|
2005-08-09 |
2007-02-15 |
Merck Patent Gmbh |
Pyrazolderivate
|
AR056582A1
(es)
*
|
2005-10-28 |
2007-10-10 |
Lilly Co Eli |
COMPUESTOS DE PIRAZOLIL UREA CON ACTIVIDAD INHIBITORIA DE CINASA P38 Y FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE
|
JP2009513649A
(ja)
*
|
2005-10-28 |
2009-04-02 |
イーライ リリー アンド カンパニー |
キナーゼ阻害剤
|
JP5331485B2
(ja)
|
2005-12-21 |
2013-10-30 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
癌および他の障害の処置に有用な置換ピリミジン誘導体
|
EP2036557B1
(de)
|
2006-05-18 |
2015-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumorales mittel gegen schilddrüsenkrebs
|
EP2094268A2
(de)
|
2006-05-26 |
2009-09-02 |
Bayer HealthCare, LLC |
Arzneikombinationen mit substituierten diaryl-harnstoffen zur krebsbehandlung
|
KR101472600B1
(ko)
|
2006-08-28 |
2014-12-15 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암에 대한 항종양제
|
US20100150863A1
(en)
|
2006-12-20 |
2010-06-17 |
Bayer Pharmaceuticals Corporation |
Hydroxy methyl phenyl pyrazolyl urea compound useful in treatment of cancer
|
JP5319306B2
(ja)
|
2007-01-29 |
2013-10-16 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
未分化型胃癌治療用組成物
|
CA2682162C
(en)
|
2007-04-02 |
2016-05-10 |
Renovis, Inc. |
Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
|
AU2008242767A1
(en)
|
2007-04-20 |
2008-10-30 |
Deciphera Pharmaceuticals, Llc |
Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
|
EP1992344A1
(de)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
|
WO2009035949A2
(en)
*
|
2007-09-13 |
2009-03-19 |
Arete Therapeutics, Inc. |
Soluble epoxide hydrolase inhibitors
|
US8952035B2
(en)
|
2007-11-09 |
2015-02-10 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
PE20110598A1
(es)
|
2008-10-02 |
2011-08-31 |
Respivert Ltd |
Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
|
GB0818033D0
(en)
|
2008-10-02 |
2008-11-05 |
Respivert Ltd |
Novel compound
|
US8299073B2
(en)
|
2008-12-11 |
2012-10-30 |
Respivert Ltd. |
P38 MAP kinase inhibitors
|
CA2747398C
(en)
|
2008-12-17 |
2023-06-20 |
The Scripps Research Institute |
Generation and maintenance of stem cells
|
GB0905955D0
(en)
|
2009-04-06 |
2009-05-20 |
Respivert Ltd |
Novel compounds
|
JP5787976B2
(ja)
|
2010-04-08 |
2015-09-30 |
レスピバート・リミテツド |
P38mapキナーゼ阻害剤としてのピラゾリルウレア
|
CN102958523B
(zh)
|
2010-06-25 |
2014-11-19 |
卫材R&D管理有限公司 |
使用具有激酶抑制作用的组合的抗肿瘤剂
|
US20130183268A1
(en)
|
2010-07-19 |
2013-07-18 |
Bayer Healthcare Llc |
Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
WO2012144463A1
(ja)
|
2011-04-18 |
2012-10-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療剤
|
KR101960555B1
(ko)
|
2011-05-13 |
2019-03-20 |
어레이 바이오파마 인크. |
Trka 키나제 저해제로서의 피롤리디닐 유레아 및 피롤리디닐 티오유레아 화합물
|
US9945862B2
(en)
|
2011-06-03 |
2018-04-17 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
EP2578582A1
(de)
|
2011-10-03 |
2013-04-10 |
Respivert Limited |
1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) Harnstoffe als p38 MAP Kinasehemmer
|
BR112014007694B1
(pt)
|
2011-10-03 |
2022-09-27 |
Respivert Limited |
Compostos de 1-(3-(tert-butil)-1-(p-tolil)-1h-pirazol-5-il)-3-(4-((2-(fenilamino) pirimidin-4-il)óxi) naftalen-1-il)ureia, seus usos, composição e formulação farmacêutica compreendendo os mesmos
|
TW201332988A
(zh)
*
|
2011-12-23 |
2013-08-16 |
Millennium Pharm Inc |
雜芳基化合物及其用途
|
EP2799537B1
(de)
|
2011-12-28 |
2021-09-22 |
Kyoto Prefectural Public University Corporation |
Normalisierung der züchtung von hornhautendothelzellen
|
WO2013162027A1
(ja)
|
2012-04-27 |
2013-10-31 |
学校法人 慶應義塾 |
神経分化促進剤
|
US8461179B1
(en)
|
2012-06-07 |
2013-06-11 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
GB201214750D0
(en)
|
2012-08-17 |
2012-10-03 |
Respivert Ltd |
Compounds
|
GB201215357D0
(en)
|
2012-08-29 |
2012-10-10 |
Respivert Ltd |
Compounds
|
US9809578B2
(en)
|
2012-11-13 |
2017-11-07 |
Array Biopharma Inc. |
Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
|
US9790178B2
(en)
|
2012-11-13 |
2017-10-17 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
DK2922844T3
(en)
|
2012-11-13 |
2018-03-05 |
Array Biopharma Inc |
N-PYRROLIDINYL, N'-PYRAZOLYL-URINE, THIOURINE, GUANIDINE AND CYANOGUANIDE COMPOUNDS AS TRKA-KINASE INHIBITORS
|
US9828360B2
(en)
|
2012-11-13 |
2017-11-28 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
WO2014078408A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
WO2014078325A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
WO2014078322A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
MX366761B
(es)
|
2012-11-13 |
2019-07-23 |
Array Biopharma Inc |
Compuestos bíciclicos de urea, tiourea, guanidina y cianoguanidina útiles para el tratamiento del dolor.
|
US9546156B2
(en)
|
2012-11-13 |
2017-01-17 |
Array Biopharma Inc. |
N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
|
WO2014078331A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
BR112015009004A8
(pt)
|
2012-12-21 |
2021-07-20 |
Eisai R&D Man Co Ltd |
forma amorfa de derivado de quinolina e método de produção da mesma
|
WO2014140582A1
(en)
|
2013-03-14 |
2014-09-18 |
Respivert Limited |
Kinase inhibitors
|
MX368099B
(es)
|
2013-05-14 |
2019-09-19 |
Eisai R&D Man Co Ltd |
Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
|
WO2015066490A1
(en)
|
2013-10-31 |
2015-05-07 |
Ohio University |
Prevention and treatment of non-alcoholic fatty liver disease
|
US10813920B2
(en)
|
2013-11-14 |
2020-10-27 |
The Doshisha |
Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
|
EA034927B1
(ru)
|
2014-02-14 |
2020-04-07 |
Респайверт Лимитед |
Ароматические гетероциклические соединения как противовоспалительные соединения
|
MA40434B1
(fr)
|
2014-05-15 |
2019-09-30 |
Array Biopharma Inc |
1-((3s,4r)-4-(3-fluorophényl)-1-(2-méthoxyéthyl)pyrrolidin-3-yl)-3-(4-méthyl-3-(2-méthylpyrimidin-5-yl)-1-phényl-1h-pyrazol-5-yl)urée comme inhibiteur de la kinase trka
|
US10023567B2
(en)
|
2014-07-18 |
2018-07-17 |
Ohio University |
Imidazole and thiazole compositions for modifying biological signaling
|
HRP20221047T1
(hr)
|
2014-08-28 |
2022-11-11 |
Eisai R&D Management Co., Ltd. |
Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
|
CN107427505A
(zh)
|
2015-02-25 |
2017-12-01 |
卫材R&D管理有限公司 |
用于抑制喹啉衍生物的苦味的方法
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
US11369623B2
(en)
|
2015-06-16 |
2022-06-28 |
Prism Pharma Co., Ltd. |
Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
|
IL277071B1
(en)
|
2018-03-08 |
2024-03-01 |
Incyte Corp |
Aminopyrizine diol compounds as PI3K–y inhibitors
|
JP2021519334A
(ja)
|
2018-03-26 |
2021-08-10 |
クリア クリーク バイオ, インコーポレイテッド |
ジヒドロオロト酸デヒドロゲナーゼを阻害するための組成物および方法
|
US11046658B2
(en)
|
2018-07-02 |
2021-06-29 |
Incyte Corporation |
Aminopyrazine derivatives as PI3K-γ inhibitors
|
WO2021030405A1
(en)
|
2019-08-12 |
2021-02-18 |
Deciphera Pharmaceuticals, Llc |
Ripretinib for treating gastrointestinal stromal tumors
|
MX2022001863A
(es)
|
2019-08-12 |
2022-05-30 |
Deciphera Pharmaceuticals Llc |
Metodos para tratar los tumores del estroma gastrointestinal.
|
RS65058B1
(sr)
|
2019-12-30 |
2024-02-29 |
Deciphera Pharmaceuticals Llc |
Formulacije inhibitora amorfne kinaze i postupci njihove primene
|
BR112022013169A2
(pt)
|
2019-12-30 |
2022-09-13 |
Deciphera Pharmaceuticals Llc |
Composições de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofeil)-3-fenilurea
|
US11779572B1
(en)
|
2022-09-02 |
2023-10-10 |
Deciphera Pharmaceuticals, Llc |
Methods of treating gastrointestinal stromal tumors
|